1. Home
  2. UBCP vs MURA Comparison

UBCP vs MURA Comparison

Compare UBCP & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UBCP

United Bancorp Inc.

HOLD

Current Price

$13.82

Market Cap

77.4M

Sector

Finance

ML Signal

HOLD

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.03

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBCP
MURA
Founded
1902
2013
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
77.4M
36.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UBCP
MURA
Price
$13.82
$2.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
6.0K
224.8K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
6.81%
N/A
EPS Growth
N/A
N/A
EPS
1.31
N/A
Revenue
$30,516,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
$10.36
N/A
Revenue Growth
4.40
N/A
52 Week Low
$12.25
$0.95
52 Week High
$15.64
$4.74

Technical Indicators

Market Signals
Indicator
UBCP
MURA
Relative Strength Index (RSI) 61.51 40.39
Support Level $13.21 $2.06
Resistance Level $14.37 $2.10
Average True Range (ATR) 0.37 0.01
MACD 0.06 -0.01
Stochastic Oscillator 66.42 25.00

Price Performance

Historical Comparison
UBCP
MURA

About UBCP United Bancorp Inc.

United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: